Long-term monitoring is essential to ensure that fatigue does not indicate an underlying complication or nutritional deficiency
If you are at a healthy weight and considering a GLP-1, the more productive question for a clinician is what specific metabolic marker you are trying to move, and whether it can be moved without a drug that will also reduce your muscle mass
Conclusion This cohort study demonstrates that semaglutide at lower doses compared to previously published is a feasible and cost-effective means of achieving weight loss for refractory obesity in post-operative bariatric patients
Pharmacy partners and state availability are not published, and the third-party review volume is smaller than Peak Wellnesss or Edens
Intention-to-treat principle
18 Overall, ALC was generally well tolerated, with predominantly mild GI and CNS events, and no evidence of excess serious AEs compared with controls